Medipost Co Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Pretoria South Africa (1991)

Organization Overview

First Clinical Trial
2008
NCT00823316
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Medipost America Inc. | Medipost Co Ltd.

Active Ingredients

Drugs in Phase 3 Trials (1)

umbilical cord mesenchymal stem cells (13 trials)

Drugs in Phase 2 Trials (2)

pneumostem (4 trials)

sodium chloride (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Bronchopulmonary Dysplasia (Phase 2)

Cartilage Diseases (Phase 2)

Dementia (Phase 1)

Graft vs Host Disease (Phase 2)

Hyperplasia (Phase 2)

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Premature Birth (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 3